- Clinical Trials
- April 2024
- 170 Pages
Global
From €1710EUR$1,750USD£1,427GBP
€2443EUR$2,500USD£2,039GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1368EUR$1,400USD£1,142GBP
€1954EUR$2,000USD£1,631GBP
- Drug Pipelines
- April 2024
- 180 Pages
Global
From €2052EUR$2,100USD£1,713GBP
€2931EUR$3,000USD£2,447GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1368EUR$1,400USD£1,142GBP
€1954EUR$2,000USD£1,631GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1368EUR$1,400USD£1,142GBP
€1954EUR$2,000USD£1,631GBP
- Report
- May 2024
- 160 Pages
Global
From €5861EUR$5,999USD£4,893GBP
- Report
- July 2024
- 59 Pages
Global
From €3903EUR$3,995USD£3,259GBP
- Report
- September 2024
- 80 Pages
Global
From €3500EUR$3,837USD£3,024GBP
- Report
- February 2024
- 86 Pages
Global
From €3500EUR$3,837USD£3,024GBP
- Report
- October 2023
- 85 Pages
United States
From €4739EUR$4,850USD£3,956GBP
- Report
- September 2019
- 29 Pages
Global
€9771EUR$10,000USD£8,157GBP
- Report
- September 2019
- 28 Pages
Global
€9771EUR$10,000USD£8,157GBP
- Report
- March 2019
- 20 Pages
Global
€9771EUR$10,000USD£8,157GBP
- Report
- March 2019
- 19 Pages
Global
€9771EUR$10,000USD£8,157GBP
- Report
- August 2018
- 25 Pages
Global
From €9771EUR$10,000USD£8,157GBP
- Report
- September 2021
- 40 Pages
China
From €2540EUR$2,600USD£2,121GBP
- Report
- July 2021
- 50 Pages
China
From €2540EUR$2,600USD£2,121GBP
- Report
- August 2022
- 115 Pages
Global
From €4397EUR$4,500USD£3,671GBP
- Report
- April 2023
- 90 Pages
Middle East, Africa
From €4641EUR$4,750USD£3,874GBP
- Report
- January 2022
- 68 Pages
Europe
From €4641EUR$4,750USD£3,874GBP
The Kidney Cancer Drugs market is a subset of the pharmaceutical industry that focuses on the development and sale of drugs used to treat kidney cancer. These drugs are used to reduce the size of tumors, slow the growth of cancer cells, and reduce the spread of cancer to other parts of the body. Common treatments include chemotherapy, targeted therapy, immunotherapy, and surgery.
The market is highly competitive, with many companies vying for market share. Major players include Bristol-Myers Squibb, Merck, Pfizer, Novartis, and AstraZeneca. These companies are constantly researching and developing new drugs to improve the treatment of kidney cancer. Additionally, many smaller companies are also involved in the market, offering innovative treatments and therapies.
Overall, the Kidney Cancer Drugs market is an important part of the pharmaceutical industry, providing treatments and therapies to improve the lives of those affected by kidney cancer. Show Less Read more